The stock of Fresenius SE KGaA (OTCPK:FSNUF, 30-year Financials) is believed to be modestly undervalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $43.345 per share and the market cap of $24.9 billion, Fresenius SE KGaA stock is believed to be modestly undervalued. GF Value for Fresenius SE KGaA is shown in the chart below.
Because Fresenius SE KGaA is relatively undervalued, the long-term return of its stock is likely to be higher than its business growth, which averaged 2.3% over the past three years and is estimated to grow 3.85% annually over the next three to five years.
Link: These companies may deliever higher future returns at reduced risk.
Investing in companies with poor financial strength has a higher risk of permanent loss of capital. Thus, it is important to carefully review the financial strength of a company before deciding whether to buy its stock. Looking at the cash-to-debt ratio and interest coverage is a great starting point for understanding the financial strength of a company. Fresenius SE KGaA has a cash-to-debt ratio of 0.08, which is worse than 89% of the companies in the industry of Healthcare Providers & Services. GuruFocus ranks the overall financial strength of Fresenius SE KGaA at 4 out of 10, which indicates that the financial strength of Fresenius SE KGaA is poor. This is the debt and cash of Fresenius SE KGaA over the past years:
It poses less risk to invest in profitable companies, especially those that have demonstrated consistent profitability over the long term. A company with high profit margins is also typically a safer investment than one with low profit margins. Fresenius SE KGaA has been profitable 10 over the past 10 years. Over the past twelve months, the company had a revenue of $42 billion and earnings of $3.534 a share. Its operating margin is 12.00%, which ranks better than 77% of the companies in the industry of Healthcare Providers & Services. Overall, GuruFocus ranks the profitability of Fresenius SE KGaA at 8 out of 10, which indicates strong profitability. This is the revenue and net income of Fresenius SE KGaA over the past years:
Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term stock performance of a company. A faster growing company creates more value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth of Fresenius SE KGaA is 2.3%, which ranks in the middle range of the companies in the industry of Healthcare Providers & Services. The 3-year average EBITDA growth rate is 4.9%, which ranks in the middle range of the companies in the industry of Healthcare Providers & Services.
Another way to evaluate a company's profitability is to compare its return on invested capital (ROIC) to its weighted cost of capital (WACC). Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the ROIC is higher than the WACC, it indicates that the company is creating value for shareholders. Over the past 12 months, Fresenius SE KGaA's ROIC was 5.16, while its WACC came in at 3.63. The historical ROIC vs WACC comparison of Fresenius SE KGaA is shown below:
In closing, the stock of Fresenius SE KGaA (OTCPK:FSNUF, 30-year Financials) gives every indication of being modestly undervalued. The company's financial condition is poor and its profitability is strong. Its growth ranks in the middle range of the companies in the industry of Healthcare Providers & Services. To learn more about Fresenius SE KGaA stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
